Wound therapy startup SironRX Therapeutics has raised $2.3 million of a possible $2.5 million funding round.
SironRx, which boasts technology pioneered at Cleveland Clinic, plans to use the funding to commence human trials, which the company says could start around the end of the year, according to CEO Rahul Aras, former director of life science commercialization with Cleveland Clinic Innovations.